Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2656.e17-2656.e23

  Hatano, Taku ^a   Funayama, Manabu ^a,b   Kubo, Shin ichiro ^a   Mata, Ignacio F ^c,d   Oji, Yutaka ^a   Mori, Akio ^a   Zabetian, Cyrus P ^c,d   Waldherr, Sarah M ^c,d   Yoshino, Hiroyo ^b   Oyama, Genko ^a   Shimo, Yasushi ^a   Fujimoto, Ken ichi ^e   Oshima, Hirokazu ^f   Kunii, Yasuto ^f   Yabe, Hirooki ^f   Mizuno, Yoshikuni ^a   Hattori, Nobutaka ^a,b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Jichi idai Station Brain Clinic   (Japan)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Asia; Intrafamilial clinical heterogeneity; LRRK2; P.R1441G; Parkinson's disease

Indexed keywords

BENSERAZIDE; CARBIDOPA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; SELEGILINE; TALIPEXOLE; TRIHEXYPHENIDYL; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; EXON; FEMALE; GENE IDENTIFICATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; JAPANESE (PEOPLE); LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PARKINSON DISEASE; PREVALENCE; SEQUENCE ANALYSIS; SPAIN; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; URUGUAY; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE REPORT; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PEDIGREE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; EXONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ANALYSIS, DNA;

EID: 84922840724     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.05.025     Document Type: Article

References (31)

1. Abe Y., Kachi T., Kato T., Arahata Y., Yamada T., Washimi Y., Iwai K., Ito K., Yanagisawa N., Sobue G. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J.Neurol. Neurosurg. Psychiatry 2003, 74:419-422.
2. Cookson M.R., Hardy J., Lewis P.A. Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol. 2008, 1:217-231.
3. Cornejo-Olivas M.R., Torres L., Mazzetti P., Cosentino C., Zabetian C.P., Mata I.F. Variable penetrance of the LRRK2-R1441G mutation in a Peruvian family [abstract]. Mov. Disord. 2013, 23(Suppl. 1):1154.
4. Deng H., Le W., Guo Y., Hunter C.B., Xie W., Huang M., Jankovic J. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J.Neurol. Sci. 2006, 251:102-106.
5. Funayama M., Li Y., Tomiyama H., Yoshino H., Imamichi Y., Yamamoto M., Murata M., Toda T., Mizuno Y., Hattori N. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007, 18:273-275.
6. Gomez-Esteban J.C., Lezcano E., Zarranz J.J., Gonzalez C., Bilbao G., Lambarri I., Rodriguez O., Garibi J. Outcome of bilateral deep brain subthalamic stimulation in patients carrying the R1441G mutation in the LRRK2 dardarin gene. Neurosurgery 2008, 62:857-863.
7. Gonzalez-Fernandez M.C., Lezcano E., Ross O.A., Gomez-Esteban J.C., Gomez-Busto F., Velasco F., Alvarez-Alvarez M., Rodriguez-Martinez M.B., Ciordia R., Zarranz J.J., Farrer M.J., Mata I.F., de Pancorbo M.M. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat. Disord. 2007, 13:509-515.
8. Hasegawa K., Stoessl T., Yokoyama T., Kowa H., Wszolek Z.K., Yagishita S. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord. 2009, 15:300-306.
9. Haugarvoll K., Wszolek Z.K. Clinical features of LRRK2 parkinsonism. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S205-S208.
10. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., Tan E.K., Gaig C., Tolosa E., Goldwurm S., Guidi M., Riboldazzi G., Brown L., Walter U., Benecke R., Berg D., Gasser T., Theuns J., Pals P., Cras P., De Deyn P.P., Engelborghs S., Pickut B., Uitti R.J., Foroud T., Nichols W.C., Hagenah J., Klein C., Samii A., Zabetian C.P., Bonifati V., Van Broeckhoven C., Farrer M.J., Wzolek Z.K. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008, 70:1456-1460.
11. Khoo T.K., Yarnall A.J., Duncan G.W., Coleman S., O'Brien J.T., Brooks D.J., Barker R.A., Burn D.J. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013, 80:276-281.
12. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., Pollak P., Brice A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N.Engl. J. Med. 2006, 354:422-423. French Parkinson's Disease Genetics Study Group.
13. Marti-Masso J.F., Ruiz-Martinez J., Bolano M.J., Ruiz I., Gorostidi A., Moreno F., Ferrer I., Lopez de Munain A. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov. Disord. 2009, 24:1998-2001.
14. Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C., Farrer M., Alvarez V. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci. Lett. 2005, 382:309-311.
15. Mata I.F., Cosentino C., Marca V., Torres L., Mazzetti P., Ortega O., Raggio V., Aljanati R., Buzo R., Yearout D., Dieguez E., Zabetian C.P. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat. Disord. 2009, 2009:370-373.
16. Mata I.F., Hutter C.M., Gonzalez-Fernandez M.C., de Pancorbo M.M., Lezcano E., Huerta C., Blazquez M., Ribacoba R., Guisasola L.M., Salvador C., Gomez-Esteban J.C., Zarranz J.J., Infante J., Jankovic J., Deng H., Edwards K.L., Alvarez V., Zabetian C.P. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics 2009, 10:347-353.
17. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., Lipton R.B., Soto-Valencia J., Risch N., Bressman S.B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N.Engl. J. Med. 2006, 354:424-425.
18. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
19. Paisan-Ruiz C., Saenz A., Lopez de Munain A., Marti I., Martinez Gil A., Marti-Masso J.F., Perez-Tur J. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann. Neurol. 2005, 57:365-372.
20. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., Litvan I., Gordon M.F., Wszolek Z.K., Farrer M.J., Dickson D.W. Lrrk2 and Lewy body disease. Ann. Neurol. 2006, 59:388-393.
21. Ross O.A., Spanaki C., Griffith A., Lin C.H., Kachergus J., Haugarvoll K., Latsoudis H., Plaitakis A., Ferreira J.J., Sampaio C., Bonifati V., Wu R.M., Zabetian C.P., Farrer M.J. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat. Disord. 2009, 15:466-467.
22. Ross O.A., Soto-Ortolaza A.I., Heckman M.G., Aasly J.O., Abahuni N., Annesi G., Bacon J.A., Bardien S., Bozi M., Brice A., Brighina L., Van Broeckhoven C., Carr J., Chartier-Harlin M.C., Dardiotis E., Dickson D.W., Diehl N.N., Elbaz A., Ferrarese C., Ferraris A., Fiske B., Gibson J.M., Gibson R., Hadjigeorgiou G.M., Hattori N., Ioannidis J.P., Jasinska-Myga B., Jeon B.S., Kim Y.J., Klein C., Kruger R., Kyratzi E., Lesage S., Lin C.H., Lynch T., Maraganore D.M., Mellick G.D., Mutez E., Nilsson C., Opala G., Park S.S., Puschmann A., Quattrone A., Sharma M., Silburn P.A., Sohn Y.H., Stefanis L., Tadic V., Theuns J., Tomiyama H., Uitti R.J., Valente E.M., van de Loo S., Vassilatis D.K., Vilarino-Guell C., White L.R., Wirdefeldt K., Wszolek Z.K., Wu R.M., Farrer M.J. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908. Genetic Epidemiology Of Parkinson's Disease, Consortium.
23. Ruiz-Martinez J., Gorostidi A., Goyenechea E., Alzualde A., Poza J.J., Rodriguez F., Bergareche A., Moreno F., Lopez de Munain A., Marti Masso J.F. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Mov. Disord. 2011, 26:2026-2031.
24. Simon-Sanchez J., Marti-Masso J.F., Sanchez-Mut J.V., Paisan-Ruiz C., Martinez-Gil A., Ruiz-Martinez J., Saenz A., Singleton A.B., Lopez de Munain A., Perez-Tur J. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov. Disord. 2006, 21:1954-1959.
25. Tan E.K., Shen H., Tan L.C., Farrer M., Yew K., Chua E., Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C., Yih Y., Skipper L., Liu J.J. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci. Lett. 2005, 384:327-329.
26. Tijero B., Gomez Esteban J.C., Somme J., Llorens V., Lezcano E., Martinez A., Rodriguez T., Berganzo K., Zarranz J.J. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat. Disord. 2013, 19:906-909.
27. Tomiyama H., Li Y., Funayama M., Hasegawa K., Yoshino H., Kubo S.I., Sato K., Hattori T., Lu C.S., Inzelberg R., Djaldetti R., Melamed E., Amouri R., Gouider-Khouja N., Hentati F., Hatano Y., Wang M., Imamichi Y., Mizoguchi K., Miyajima H., Obata F., Toda T., Farrer M.J., Mizuno Y., Hattori N. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov. Disord. 2006, 21:1102-1108.
28. Ujiie S., Hatano T., Kubo S.I., Imai S., Sato S., Uchihara T., Yagishita S., Hasegawa K., Kowa H., Sakai F., Hattori N. LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat. Disord. 2012, 18:819-823.
29. Yescas P., Lopez M., Monroy N., Boll M.C., Rodriguez-Violante M., Rodriguez U., Ochoa A., Alonso M.E. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Neurosci. Lett. 2010, 485:79-82.
30. Zabetian C.P., Morino H., Ujike H., Yamamoto M., Oda M., Maruyama H., Izumi Y., Kaji R., Griffith A., Leis B.C., Roberts J.W., Yearout D., Samii A., Kawakami H. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 2006, 67:697-699.
31. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.